Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 18/20 | 0.84 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2106671 | 0.93 | ALOX5AP (0.89) | ALOX5APALOX5CYP3A4CYP2C9PTGS1 | |
| SCHEMBL2108478 | 0.91 | ALOX5AP (1.00) | ALOX5APALOX5CYP3A4CYP2C9PTGS1 | |
| SCHEMBL9178666 | 0.84 | ALOX5AP (0.76) | ALOX5APALOX5CYP3A4CYP2C9PTGS1 | |
| SCHEMBL9584575 | 0.84 | ALOX5AP (0.80) | ALOX5APALOX5CYP3A4CYP2C9PTGS1 | |
| SCHEMBL2108514 | 0.83 | ALOX5AP (0.85) | ALOX5APALOX5CYP3A4CYP2C9PTGS1 | |
| SCHEMBL9176433 | 0.83 | ALOX5AP (1.00) | ALOX5APALOX5CYP3A4CYP2C9PTGS1 | |
| SCHEMBL2107877 | 0.83 | PTGS1 (0.86) | ALOX5APALOX5CYP3A4CYP2C9PTGS1 | |
| SCHEMBL9048306 | 0.83 | ALOX5AP (0.84) | ALOX5APALOX5CYP3A4CYP2C9PTGS1 | |
| SCHEMBL9736625 | 0.82 | PTGES2 (0.71) | ALOX5APALOX5CYP3A4CYP2C9 | |
| SCHEMBL9387953 | 0.82 | ALOX5AP (1.00) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0419049-B1 | (Quinolin-2-ylmethoxy) indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA INC (CA) | 1995-04-12 | — | — | EP | claimed |
| WO-1994013293-A2 | (QUINOLIN-2-YLMETHOXY)INDOLES AS INHIBITORS OF THE BIOSYNTHESIS OF LEUKOTRIENES | MERCK FROSST CANADA INC. (CA) | 1994-06-23 | — | — | WO | claimed |
| US-5204344-A | (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA, INC. (CA) | 1993-04-20 | — | — | US | claimed |
| EP-0419049-A1 | (Quinolin-2-ylmethoxy) indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA INC. (CA) | 1991-03-27 | — | — | EP | claimed |
| US-8158362-B2 | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype | DECODE GENETICS EHF. (IS) | 2012-04-17 | — | — | US | disclosed |
| US-7851486-B2 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS EHF. (IS) | 2010-12-14 | — | — | US | disclosed |
| US-20100216863-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment | DECODE GENETICS EHF. (IS) | 2010-08-26 | — | — | US | disclosed |
| US-20080293750-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment | DECODE GENETICS EHF. (IS) | 2008-11-27 | — | — | US | disclosed |
| EP-1871908-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION, STROKE AND PAOD; METHODS OF TREATMENT | Decode Genetics EHF. (IS) | 2008-01-02 | — | — | EP | disclosed |
| US-20070280917-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS, INC. (IS) | 2007-12-06 | — | — | US | disclosed |
| EP-1718284-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFRACTION, STROKE, AND PAOD; METHODS OF TREATMENT | Decode Genetics EHF. (IS) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006105439-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION, STROKE. AND PAOD; METHODS OF TREATMENT | DECODE GENETICS EHF. (IS) | 2006-10-05 | — | — | WO | disclosed |
| WO-2005075022-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFRACTION, STROKE, AND PAOD; METHODS OF TREATMENT | DECODE GENETICS EHF. (IS) | 2005-08-18 | — | — | WO | disclosed |
| US-20050113408-A1 | peripheral arterial occlusive disease (PAOD); prophylaxis of myocardial infarction by administering an agent that inhibits leukotriene synthesis in vivo for example (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, BAY-X-1005 | DECODE GENETICS EHF. (IS) | 2005-05-26 | — | — | US | disclosed |
| EP-0419049-B1 | (Quinolin-2-ylmethoxy) indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA INC (CA) | 1995-04-12 | — | — | EP | disclosed |
| US-5380850-A | Quinoline hydrazine intermediates | MERCK FROSST CANADA, INC. (CA) | 1995-01-10 | — | — | US | disclosed |
| WO-1994013293-A2 | (QUINOLIN-2-YLMETHOXY)INDOLES AS INHIBITORS OF THE BIOSYNTHESIS OF LEUKOTRIENES | MERCK FROSST CANADA INC. (CA) | 1994-06-23 | — | — | WO | disclosed |
| US-5272145-A | (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA, INC. (CA) | 1993-12-21 | — | — | US | disclosed |
| US-5204344-A | (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA, INC. (CA) | 1993-04-20 | — | — | US | disclosed |
| EP-0419049-A1 | (Quinolin-2-ylmethoxy) indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA INC. (CA) | 1991-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216863-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment | ALOX15B, ALOX15, ALOX5 | ALOX5AP 8/4885ALOX5 3/4885CYP3A4 1021/4885 |
| US-20070280917-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | ALOX15B, ALOX15, ALOX5 | ALOX5AP 8/4885ALOX5 3/4885CYP3A4 1021/4885 |
| US-20080293750-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment | PLAAT3, PLAAT2, PLA2G7 | ALOX5AP 32/4885ALOX5 14/4885CYP3A4 3210/4885 |
| US-20050113408-A1 | peripheral arterial occlusive disease (PAOD); prophylaxis of myocardial infarction by administering an agent that inhibits leukotriene synthesis in vivo for example (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, BAY-X-1005 | ALOX5, ALOX15, ALOX12 | ALOX5AP 6/4885ALOX5 1/4885CYP3A4 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.